Results 91 to 100 of about 6,848 (153)

Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy. [PDF]

J Neurol
Kleinschnitz C, Skripuletz T, Pfeuffer S, Pawlitzki M, Rieckmann P, Penner IK, Knaup J, Wagner T, Hübschen M, Hellwig K, Pul R.   +10 more
europepmc   +1 more source

Catheter-associated bacteremia caused by Asaia lannensis in an immunosuppressed patient: a case report. [PDF]

BMC Infect Dis
Simonet TM, Bertelli C, Mraihi H, Opota O, Poirel L, Tissot F, Lemaire B.   +6 more
europepmc   +1 more source

Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Kuiper KL, Bogers L, Rip J, van Hasselt Y, Melief MJ, Wierenga-Wolf AF, Klein Kranenbarg RAM, Bindels E, van de Werken HJG, de Beukelaar J, Smets I, Wokke B, Smolders J, van Luijn MM.   +13 more
europepmc   +1 more source

Switching high efficacy therapies in Multiple Sclerosis: Does real world experience support such a strategy? [PDF]

Neurotherapeutics
Dhib-Jalbut S.
europepmc   +1 more source

Cyclodextrin Complexes for Clinical Translatability: Applications for Cladribine and Retrometabolically Designed Estredox. [PDF]

Int J Mol Sci
Bodor N, Buchwald P.
europepmc   +1 more source

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Smirnov RA, Cantoni C, Lee K, Agnihotri RA, Axtell RC, Salter A, Lancia S, Paley MA, Hayward B, Korich J, Evans E, Pardo G, Obeidat AZ, Stuve O, Bar-Or A, Artyomov MN, Cross AH, Edelson BT, Wu GF.   +18 more
europepmc   +1 more source

Case Report: Complete remission of refractory Langerhans cell sarcoma following CLAG-M chemotherapy and allogeneic hematopoietic stem cell transplant. [PDF]

Front Oncol
Mades A, Chow L, Ghezavati A, Ali A, Schiff K, Savitala-Damerla L, Siddiqi I, Tang B, Yaghmour G.   +8 more
europepmc   +1 more source

Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system. [PDF]

Int J Clin Pharm
Hu Y, He J, Tu Z, Ye H, Zhuang C, Jin Z, Hu H, Zhao Y, Zheng Y, Yao Q.   +9 more
europepmc   +1 more source

Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies. [PDF]

J Pers Med
Shah PV, Ng A, Shih A, Pham T, Wang J, Khalili H, Chiang CH, Singhal A, Rosenberg A, Ko S, Wallin M, Gladstone DE.   +11 more
europepmc   +1 more source

Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. [PDF]

Eur J Case Rep Intern Med
Melício A, Gonçalves HD, Dias M, Vasconcelos-Teixeira S, Madeira Lopes J.   +4 more
europepmc   +1 more source